Literature DB >> 32562668

Targeting the blood-nerve barrier for the management of immune-mediated peripheral neuropathies.

Evan B Stubbs1.   

Abstract

Healthy peripheral nerves encounter, with increased frequency, numerous chemical, biological, and biomechanical forces. Over time and with increasing age, these forces collectively contribute to the pathophysiology of a spectrum of traumatic, metabolic, and/or immune-mediated peripheral nerve disorders. The blood-nerve barrier (BNB) serves as a critical first-line defense against chemical and biologic insults while biomechanical forces are continuously buffered by a dense array of longitudinally orientated epineural collagen fibers exhibiting high-tensile strength. As emphasized throughout this Experimental Neurology Special Issue, the BNB is best characterized as a functionally dynamic multicellular vascular unit comprised of not only highly specialized endoneurial endothelial cells, but also associated perineurial cells, pericytes, Schwann cells, basement membrane, and invested axons. The composition of the BNB, while anatomically distinct, is not functionally dissimilar to that of the well characterized neurovascular unit of the central nervous system. While the BNB lacks a glial limitans and an astrocytic endfoot layer, the primary function of both vascular units is to establish, maintain, and protect an optimal endoneurial (PNS) or interstitial (CNS) fluid microenvironment that is vital for proper neuronal function. Altered endoneurial homeostasis as a secondary consequence of BNB dysregulation is considered an early pathological event in the course of a variety of traumatic, immune-mediated, or metabolically acquired peripheral neuropathies. In this review, emerging experimental advancements targeting the endoneurial microvasculature for the therapeutic management of immune-mediated inflammatory peripheral neuropathies, including the AIDP variant of Guillain-Barré syndrome, are discussed. Published by Elsevier Inc.

Entities:  

Keywords:  Basement membrane; Blood nerve barrier; Chronic pain; Endoneurial endothelial cells; Leukocytes; Nanotherapy; Pericytes; Perineurial cells; Therapeutics

Year:  2020        PMID: 32562668      PMCID: PMC7484028          DOI: 10.1016/j.expneurol.2020.113385

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  143 in total

1.  The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling.

Authors:  Marcus Buschbeck; Axel Ullrich
Journal:  J Biol Chem       Date:  2004-11-17       Impact factor: 5.157

2.  Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.

Authors:  Valeria Arkadash; Gal Yosef; Jason Shirian; Itay Cohen; Yuval Horev; Moran Grossman; Irit Sagi; Evette S Radisky; Julia M Shifman; Niv Papo
Journal:  J Biol Chem       Date:  2017-01-13       Impact factor: 5.157

3.  Isolation and culture of bovine endothelial cells of endoneurial origin.

Authors:  T Kanda; T Iwasaki; M Yamawaki; K Ikeda
Journal:  J Neurosci Res       Date:  1997-09-15       Impact factor: 4.164

4.  Establishment and characterization of human peripheral nerve microvascular endothelial cell lines: a new in vitro blood-nerve barrier (BNB) model.

Authors:  Masaaki Abe; Yasuteru Sano; Toshihiko Maeda; Fumitaka Shimizu; Yoko Kashiwamura; Hiroyo Haruki; Kazuyuki Saito; Ayako Tasaki; Motoharu Kawai; Tetsuya Terasaki; Takashi Kanda
Journal:  Cell Struct Funct       Date:  2012-05-19       Impact factor: 2.212

5.  Antinociception by neutrophil-derived opioid peptides in noninflamed tissue--role of hypertonicity and the perineurium.

Authors:  H L Rittner; D Hackel; R-S Yamdeu; S A Mousa; C Stein; M Schäfer; A Brack
Journal:  Brain Behav Immun       Date:  2009-02-20       Impact factor: 7.217

6.  Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).

Authors:  Eyup Akgün; Muhammad I Javed; Mary M Lunzer; Michael D Powers; Yuk Y Sham; Yoshikazu Watanabe; Philip S Portoghese
Journal:  J Med Chem       Date:  2015-10-20       Impact factor: 7.446

Review 7.  Barrier function in the peripheral and central nervous system-a review.

Authors:  A K Reinhold; H L Rittner
Journal:  Pflugers Arch       Date:  2016-12-12       Impact factor: 3.657

Review 8.  The Role of CC-Chemokines in the Regulation of Angiogenesis.

Authors:  Anisyah Ridiandries; Joanne T M Tan; Christina A Bursill
Journal:  Int J Mol Sci       Date:  2016-11-08       Impact factor: 5.923

9.  Neuronal sFlt1 and Vegfaa determine venous sprouting and spinal cord vascularization.

Authors:  Raphael Wild; Alina Klems; Masanari Takamiya; Yuya Hayashi; Uwe Strähle; Koji Ando; Naoki Mochizuki; Andreas van Impel; Stefan Schulte-Merker; Janna Krueger; Laetitia Preau; Ferdinand le Noble
Journal:  Nat Commun       Date:  2017-01-10       Impact factor: 14.919

10.  Transcellular migration of leukocytes is mediated by the endothelial lateral border recycling compartment.

Authors:  Zahra Mamdouh; Alexei Mikhailov; William A Muller
Journal:  J Exp Med       Date:  2009-11-02       Impact factor: 14.307

View more
  3 in total

1.  Targeting Neuroimmune Interactions in Diabetic Neuropathy with Nanomedicine.

Authors:  Mihály Balogh; Jelena M Janjic; Andrew J Shepherd
Journal:  Antioxid Redox Signal       Date:  2022-01       Impact factor: 8.401

2.  Brain Barriers and brain fluids research in 2020 and the fluids and barriers of the CNS thematic series on advances in in vitro modeling of the blood-brain barrier and neurovascular unit.

Authors:  Richard F Keep; Hazel C Jones; Lester R Drewes
Journal:  Fluids Barriers CNS       Date:  2021-05-21

3.  Tracking macrophages in diabetic neuropathy with two-color nanoemulsions for near-infrared fluorescent imaging and microscopy.

Authors:  James M Nichols; Caitlin V Crelli; Lu Liu; Hoang Vu Pham; Jelena M Janjic; Andrew J Shepherd
Journal:  J Neuroinflammation       Date:  2021-12-23       Impact factor: 8.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.